Robert E. Reiter, MD, MBA, presented “Clinical Impact of PSMA PET Prior to Prostatectomy” during the 34th International Prostate Cancer Update on February 12, 2024, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Reiter, Robert E. “Molecular Targeted Imaging.” February 2024. Accessed Nov 2024. https://grandroundsinurology.com/clinical-impact-of-psma-pet-prior-to-prostatectomy/
Clinical Impact of PSMA PET Prior to Prostatectomy – Summary
Robert E. Reiter, MD, MBA, illustrates the diagnostic and predictive value of PSMA PET imaging and the role of PSMA as a biomarker. He begins by examining the sensitivity of PSMA PET against that of MRI and the benefits of using combined PSMA PET/MRI for intermediate-risk tumors.
Dr. Reiter then turns to the functionality of PSMA PET/CT as a predictor of clinical outcome. He presents data comparing pre- and post-prostatectomy PSMA and CAPRA-(S) scores in association with biochemical recurrence, noting that PSMA outperformed CAPRA-(S) scores in some situations.
Dr. Reiter concludes by examining the utility of PSMA as a biomarker for tumor biology and how that can inform treatment. He presents data comparing tumors with high PSMA expression against those with low PSMA expression. He notes that PSMA-high tumors are responsive to primary treatment, while low-PSMA tumors are likely to require secondary treatment.
About The 34th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 34th iteration of the meeting occurred February 11-14, 2024 in Vail, Colorado. To view more educational presentations from IPCU 34, visit our collection page.
ABOUT THE AUTHOR
Robert E. Reiter, MD, MBA, is the Bing Professor of Urology and Molecular Biology and Director of the Prostate Cancer Treatment and Research Program at the David Geffen School of Medicine at the University of California, Los Angeles. He is currently the Principal Investigator of UCLA’s SPORE (Specialized Program in Research Excellence) program, a $12 million research grant from the National Cancer Institute to develop new diagnostic and treatment options for men with prostate cancer. Dr. Reiter’s clinical interests include robotic surgical management of prostate cancer and the use of both MRI and molecular imaging tools to manage this disease. His research is focused on the development of novel antibodies for both treatment and imaging of prostate cancer, as well as on the role of epithelial to mesenchymal transition in castration and treatment resistance. Dr. Reiter completed his undergraduate studies at Yale University and earned his medical degree at Stanford University Medical School.
